April 26, 2017 10:17 AM EDT

Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring

→ Analysts took a look at the data on Amgen’s latest Phase III for CGRP migraine drug erenumab (AMG334) and came away reassured, but …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

An­a­lysts of­fer a luke­warm en­dorse­ment to Am­gen for PhI­II mi­graine da­ta; Ar­sa­nis rais­es $45.5M Se­ries D; Co­v­ance faces re­struc­tur­ing